Vardenafil

• CAT Number: I002729
• CAS Number: 224785-90-4
• Molecular Formula: C23H32N6O4S
• Molecular Weight: 488.607
• Purity: ≥95%
• Synonyms: 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one
• Target: Phosphodiesterase (PDE)
• Solubility: water: 0.11 mg/ml
• Storage: Store at -20°C
• InChI: InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30)
• InChIKey: SECKRCOLJRRGGV-UHFFFAOYSA-N
• SMILES: CCCC1=NC(=C2N1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C

Vardenafil(CAT: I002729) represents a significant breakthrough in the realm of pharmacological interventions for erectile dysfunction. As a selective phosphodiesterase type 5 (PDE5) inhibitor, Vardenafil plays a pivotal role in enhancing erectile function by modulating cyclic guanosine monophosphate (cGMP) levels. By inhibiting PDE5, Vardenafil promotes the relaxation of smooth muscle cells in the penile region, allowing increased blood flow and facilitating the physiological processes necessary for achieving and maintaining an erection.

Reference

[1]. Saenz de Tejada, I., et al., The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res, 2001. 13(5): p. 282-90.
[2]. Goldstein, I., et al., Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care, 2003. 26(3): p. 777-83.